682812-79-9

Basic information

• Product Name: Carbamic acid, [2,3-dihydro-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3 -yl]-, phenylmethyl ester
• CAS NO: 682812-79-9
• Molecular Formula: C24H18F3N3O3
• Molecular Weight: 453.42
• Mol File: 682812-79-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [2,3-dihydro-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3 -yl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2,3-dihydro-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3 -yl]-, phenylmethyl ester(682812-79-9)
• EPA Substance Registry System: Carbamic acid, [2,3-dihydro-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3 -yl]-, phenylmethyl ester(682812-79-9)

Safety Data

• Hazardous Substances Data: 682812-79-9(Hazardous Substances Data)

Upstream product

• 682812-78-8 {Benzotriazol-1-yl-[2-(4-trifluoromethyl-benzoyl)-phenylcarbamoyl]-methyl}-carbamic Acid Benzyl Ester 
• 621-84-1 O-benzyl carbamate 
• 120301-10-2 N-(2-(4-(trifluoromethyl)benzoyl)phenyl)acetamide 
• 790-10-3 (2-Amino-phenyl)-(4-trifluoromethyl-phenyl)-methanone 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 517874-18-9 (Benzotriazol-1-yl-chlorocarbonyl-methyl)-carbamic acid benzyl ester 
• 124676-19-3 2-(benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 
• 133776-41-7 anthranilic acid N-methoxy-N-methylamide 

Downstream Products

• 682812-80-2 [(3S)-1-Methyl-2-oxo-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-1H benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 682812-96-0 [(3S)-1-methyl-2-oxo-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-1H benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 924279-40-3 3-amino-5-(4-trifluoromethylphenyl)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 

Relevant articles and documents

Design and synthesis of benzoazepinone-derived cyclic malonamides and aminoamides as potent γ-secretase inhibitors

We report the synthesis of benzoazepine-derived cyclic malonamides (2) and aminoamides (3) as γ-secretase inhibitors for the potential treatment of Alzheimer's disease. The in vitro structure-activity relationships of 2 and 3 along with dog pharmacokineti

Tetrazolylpropionamides as inhibitors of Abeta protein production

This invention relates to novel tetrazolylpropionamides in which the amide group comprises an aminoazepinone, and related structures, of Formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, their pharmaceutical compositions and metho